Komunikaty PR

Antiemetic Drugs Market Size to Reach 30.4B USD by 2035, Growing at a CAGR of 3.62% | Teva Pharmaceuticals

2025-04-15  |  14:55:05
Antiemetic Drugs Market

Antiemetic Drugs Market

As per MRFR analysis, the Antiemetic Drugs Market Growth Size was estimated at 19.83 (USD Billion) in 2023.

US, NY, UNITED STATES, April 15, 2025 /EINPresswire.com/ -- The global antiemetic drugs market is a vital component of the pharmaceutical industry, focused on the development and distribution of medications that prevent and treat nausea and vomiting. These symptoms are commonly associated with conditions such as motion sickness, gastroenteritis, pregnancy (morning sickness), and the side effects of treatments like chemotherapy, radiation therapy, and anesthesia. The market includes a wide range of drug classes, including serotonin receptor antagonists, dopamine antagonists, antihistamines, and others, each catering to different underlying causes of nausea and vomiting.

As per MRFR analysis, the Antiemetic Drugs Market Growth Size was estimated at 19.83 (USD Billion) in 2023. The Antiemetic Drugs Market is expected to grow from 20.55 (USD Billion) in 2024 to 30.4 (USD Billion) by 2035. The Antiemetic Drugs Market CAGR (growth rate) is expected to be around 3.62% during the forecast period (2025 - 2035).

Get Free Sample PDF Copy of This Report - https://www.marketresearchfuture.com/sample_request/43541

Top Antiemetic Drugs Market Companies

Amgen

Bristol-Myers Squibb

Sanofi

Mylan

Johnson and Johnson

Teva Pharmaceuticals

Merck

Eisai

AbbVie

GlaxoSmithKline

Allergan

Roche

Purdue Pharma

AstraZeneca

Novartis

The antiemetic drugs market is witnessing significant growth driven by rising incidences of nausea and vomiting associated with various health conditions like cancer, pregnancy, and postoperative recovery. The growing awareness of healthcare and patient outcomes is prompting increased demand for effective antiemetic treatments.

Moreover, advancements in drug formulations and delivery systems have improved the efficacy and safety profiles of these medications, making them more appealing to healthcare providers and patients alike.

Buy Now - https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=43541

Industry Detailed Segmentation:

Antiemetic Drugs Market Segmentation Insights

Antiemetic Drugs Market Drug Type Outlook

Serotonin Antagonists

Dopamine Antagonists

Antihistamines

Glucocorticoids

Neurokinin-1 Antagonists

Antiemetic Drugs Market Administration Route Outlook

Oral

Injectable

Transdermal

Rectal

Antiemetic Drugs Market Therapeutic Area Outlook

Nausea

Vomiting

Chemotherapy-Induced Nausea

Post-Operative Nausea

Motion Sickness

Antiemetic Drugs Market End User Outlook

Hospitals

Home Care

Specialty Clinics

Ambulatory Surgical Centers

Antiemetic Drugs Market Regional Outlook

North America

Europe

South America

Asia Pacific

Middle East and Africa

The Antiemetic Drugs Market is experiencing significant growth due to the rising incidence of various medical conditions associated with nausea and vomiting. Conditions such as chemotherapy-induced nausea, motion sickness, and postoperative nausea are prevalent, leading to increased demand for effective antiemetic medications. With advancements in healthcare and an increase in cancer treatments, the need for managing side effects like nausea is more critical than ever.As the patient population grows, particularly among the elderly and those undergoing complex medical treatments, the demand for antiemetic drugs is expected to rise.

Read More Details - https://www.marketresearchfuture.com/reports/antiemetics-drugs-market-43541

Relief from Nausea and Vomiting: These drugs are designed to effectively manage and alleviate nausea and vomiting, improving the quality of life for patients undergoing treatments like chemotherapy or experiencing conditions like gastroenteritis.

Improved Patient Compliance: By preventing nausea and vomiting, antiemetics can make medical treatments, particularly chemotherapy and radiation therapy, more tolerable. This helps increase patient compliance and ensures that they can complete their prescribed treatment regimens.

Variety of Options: There are several classes of antiemetic drugs, such as serotonin antagonists, dopamine antagonists, antihistamines, and corticosteroids. This variety allows for tailored treatments depending on the underlying cause of nausea and vomiting.

Management of Motion Sickness: Antiemetic drugs, like antihistamines, are commonly used to prevent or treat motion sickness, helping individuals enjoy travel or activities without the discomfort of nausea.

Gastrointestinal Disorder Management: These drugs help individuals suffering from gastrointestinal conditions like gastroesophageal reflux disease (GERD), peptic ulcers, or gastritis by controlling nausea and vomiting, improving overall comfort.

Market Growth Opportunities: As more conditions are identified that can benefit from antiemetic treatment (such as post-surgical nausea or pregnancy-related nausea), the demand for these drugs continues to grow, creating significant market opportunities for pharmaceutical companies.

Advancements in Drug Formulations: With continued research and development, newer formulations of antiemetic drugs are emerging that offer better efficacy, fewer side effects, and more convenient dosage forms (such as oral, injectable, or transdermal).

Global Demand: The global increase in cancer treatments, especially chemotherapy, has expanded the demand for antiemetic drugs, as nausea and vomiting are common side effects of these therapies. This has driven the market's growth, particularly in oncology.

More Related Reports:

US Telehealth Market: https://www.marketresearchfuture.com/s/us-telehealth-market-44089

China Dental Anesthesia Market: https://www.marketresearchfuture.com/s/china-dental-anesthesia-market-44675

France Dental Anesthesia Market: https://www.marketresearchfuture.com/s/france-dental-anesthesia-market-44670

GCC Dental Anesthesia Market: https://www.marketresearchfuture.com/s/gcc-dental-anesthesia-market-44671

Germany Dental Anesthesia Market: https://www.marketresearchfuture.com/s/germany-dental-anesthesia-market-44668

India Dental Anesthesia Market: https://www.marketresearchfuture.com/s/india-dental-anesthesia-market-44674

Italy Dental Anesthesia Market: https://www.marketresearchfuture.com/s/italy-dental-anesthesia-market-44672

About Us

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. MRFR’s approach combines the proprietary information with various data sources to give an extensive understanding to the client about the latest key developments, expected events and also about what action to take based on these aspects.

Market Research Future
Market Research Future
+1 855-661-4441
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire BRAK ZDJĘCIA
2025-07-12 | 17:55:18

Texas Professional Roofing delivers full‑spectrum roofing excellence statewide!

Texas Professional Roofing delivers full‑spectrum roofing excellence statewide!roofing-in-texasGAF sovereign shingles Texasarchitectural shingle roofing TexasArchitectural shingle roofing Texas experts using GAF Sovereign Shingles. Trusted
EIN Newswire BRAK ZDJĘCIA
2025-07-12 | 16:55:08

Noblie Paracord Beads Launch Elevates Knife Lanyards and Outdoor Style

Noblie Skull BeadsNoblie Paracord BeadsNoblie Lanyard BeadsHand-finished silver and bronze paracord beads by Noblie add weight, grip, and style to knife lanyards, bracelets, and keychains—available now.Paracord is humble, but it deserves better
EIN Newswire BRAK ZDJĘCIA
2025-07-12 | 16:55:08

Whole-Body Wins: Sparrow Health & Performance Secures 2025 Best of Alabama Award

BIRMINGHAM, AL, UNITED STATES, July 12, 2025 /EINPresswire.com/ -- Sparrow Health & Performance, Alabama’s leading natural-first health and wellness clinic, has been named a 2025 Best of Alabama winner, honoring their innovative approach to

Więcej ważnych informacji

Jedynka Newserii

Jedynka Newserii

Kongres Profesjonalistów Public Relations

Handel

Polskie MŚP otrzymają większe wsparcie w ekspansji międzynarodowej. To cel nowej inicjatywy sześciu instytucji

Firmy z sektora małych i średnich przedsiębiorstw otrzymają kompleksowe wsparcie na potrzeby zwiększania konkurencyjności na arenie międzynarodowej. Taki jest cel wspólnej inicjatywy instytucji zrzeszonych w Grupie PFR pod szyldem Team Poland. Obejmuje ona zarówno wsparcie kapitałowe, w postaci gwarancji, pożyczek czy ubezpieczenia, jak i doradztwo oraz wsparcie promocyjne i informacyjne, dzięki czemu mikro-, małym i średnim firmom łatwiej będzie podjąć decyzję o ekspansji zagranicznej. Pierwszy projekt dotyczy wsparcia dla firm zainteresowanych uczestnictwem w odbudowie Ukrainy.

Bankowość

RPP zgodna co do potrzeby obniżania stóp procentowych. Trwają dyskusje dotyczące tempa tych decyzji

W lipcu Rada Polityki Pieniężnej po raz drugi w tym roku obniżyła stopy procentowe, określając swój ruch mianem dostosowania. W kolejnych miesiącach można oczekiwać kolejnych obniżek, ale ich tempo i termin będą zależeć od efektów dotychczasowych decyzji i wzrostu płac. Docelowo główna stopa procentowa ma wynosić 3,5 proc. Te okoliczności sprzyjają kredytobiorcom.

Handel

Umowa z krajami Mercosur coraz bliżej. W. Buda: Polska nie wykorzystała swojej prezydencji do jej zablokowania

– Polska podczas prezydencji w Radzie UE nie wykorzystała szansy na obronę swoich interesów w sprawie umowy z krajami Mercosur – ocenia europoseł PiS Waldemar Buda. W jego ocenie polski rząd, mimo sprzeciwu wobec zapisów umowy, nie zbudował w UE sojuszy niezbędnych do jej odrzucenia. Porozumienie o wolnym handlu spotyka się przede wszystkim z protestami europejskich rolników, którzy obawiają się zalania wspólnego rynku tańszą żywnością z krajów Ameryki Południowej. Według europosła wszystko może się rozegrać w najbliższych tygodniach.

Partner serwisu

Instytut Monitorowania Mediów

Szkolenia

Akademia Newserii

Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a  także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.